R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-risk HPV Infection and Biopsy-proven CIN1
Conditions
High-risk HPV Infection and Biopsy-proven CIN1
Trial Timeline
Feb 1, 2014 → Dec 30, 2015
NCT ID
NCT02065973About R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 is a phase 1 stage product being developed by PDS Biotechnology for High-risk HPV Infection and Biopsy-proven CIN1. The current trial status is completed. This product is registered under clinical trial identifier NCT02065973. Target conditions include High-risk HPV Infection and Biopsy-proven CIN1.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02065973 | Phase 1 | Completed |
Competing Products
13 competing products in High-risk HPV Infection and Biopsy-proven CIN1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone | Amgen | Phase 2 | 51 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone | Gilead Sciences | Phase 3 | 76 |
| Darolutamide + ADT | Bayer | Phase 2 | 49 |
| Esmolol | Baxter | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells) | ImmunityBio | Phase 2 | 49 |
| N-803 + ETBX-071 + M-CENK | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| RP2 Injection | Replimune | Phase 2 | 44 |